Fig. 4
- ID
- ZDB-FIG-221210-12
- Publication
- Xiong et al., 2021 - SLC1A1 mediated glutamine addiction and contributed to natural killer T-cell lymphoma progression with immunotherapeutic potential
- Other Figures
- All Figure Page
- Back to All Figure Page
SLC1A1-mediated glutamine addition and malignant phenotype in NKTCL. (a, b, and c) SLC1A1 expression (a), cell proliferation (b) and colony formation (c) of NK-92 cells transfected with SLC1A1 vector or control vector and SNK-6 cells transfected with SLC1A1 shRNA or scramble. (d) Cell viability of NK-92 cells transfected with SLC1A1 vector or control vector under glutamine-depleted medium. (e and f) Cell growth inhibition (e) and colony formation (f) of NK-92 cells transfected with SLC1A1 vector under indicated culture medium. (g) IC50 of NK-92 cells transfected with SLC1A1 vector or control vector and SNK-6 cells transfected with SLC1A1 shRNA or scramble treated with asparaginase. (h) Tumor formation of NK-92 cells transfected with SLC1A1 vector or control vector under indicated number of injected cells in xenograft zebrafish models. (i) Survival of xenograft zebrafish models injected with NK-92 cells transfected with SLC1A1 vector or control vector upon asparaginase treatment (0.5 IU/mL). All the assays were set up in triplicate. Data in (a), (b), (c), (d), (e), (f), (g) and (h) were represented as mean ± SD. P values in (a), (b), (c), (d), (e), (f), (g) and (h)were calculated with unpaired t-test. P values in (i) were calculated with log-rank test. |